Smith Michael D, Sheppard Carmen L, Hogan Angela, Harrison Timothy G, Dance David A B, Derrington Petra, George Robert C
Department of Microbiology, Musgrove Park Hospital, Taunton, Somerset, United Kingdom.
J Clin Microbiol. 2009 Apr;47(4):1046-9. doi: 10.1128/JCM.01480-08. Epub 2009 Feb 18.
The diagnosis of severe Streptococcus pneumoniae infection relies heavily on insensitive culture techniques. To improve the usefulness of PCR assays, we developed a dual-PCR protocol (targeted at pneumolysin and autolysin) for EDTA blood samples. This was compared to the Binax NOW S. pneumoniae urine antigen test in patients with bacteremic pneumococcal infections. Patients with nonbacteremic community-acquired pneumonia also were tested by these methods to determine what proportion could be confirmed as pneumococcal infections. A direct comparison was made in a group of patients who each had both tests performed. The Binax NOW S. pneumoniae urine antigen test was positive in 51 of 58 bacteremic pneumococcal cases (sensitivity, 88%; 95% confidence interval [CI], 77 to 95%), whereas the dual PCR was positive in 31 cases (sensitivity, 53.5%; 95% CI, 40 to 67%; P < 0.0001), and all of these had detectable urinary antigens. Both tests gave positive results in 2 of 51 control patients (referred to as other-organism septicemia), giving a specificity of 96% (95% CI, 86.5 to 99.5%). In 77 patients with nonbacteremic community-acquired pneumonia, urinary antigen was detected significantly more often (in 21 patients [27%]) than a positive result by the dual-PCR protocol (6 [8%]) (P = 0.002). The development of a dual-PCR protocol enhanced the sensitivity compared to that of the individual assays, but it is still significantly less sensitive than the Binax NOW urine antigen test, as well as being more time-consuming and expensive. Urinary antigen detection is the nonculture diagnostic method of choice for patients with possible severe pneumococcal infection.
重症肺炎链球菌感染的诊断严重依赖于不敏感的培养技术。为提高聚合酶链反应(PCR)检测的实用性,我们针对乙二胺四乙酸(EDTA)抗凝血样本开发了一种双重PCR方案(靶向肺炎溶血素和自溶素)。将其与用于菌血症性肺炎球菌感染患者的Binax NOW肺炎链球菌尿抗原检测进行比较。还通过这些方法对非菌血症性社区获得性肺炎患者进行检测,以确定可被确认为肺炎球菌感染的患者比例。对一组同时进行了两种检测的患者进行了直接比较。在58例菌血症性肺炎球菌病例中,51例Binax NOW肺炎链球菌尿抗原检测呈阳性(敏感性为88%;95%置信区间[CI]为77%至95%),而双重PCR检测在31例中呈阳性(敏感性为53.5%;95%CI为40%至67%;P<0.0001),并且所有这些病例的尿抗原均可检测到。在51例对照患者(称为其他生物体败血症)中,两种检测均有2例呈阳性结果,特异性为96%(95%CI为86.5%至99.5%)。在77例非菌血症性社区获得性肺炎患者中,尿抗原检测呈阳性的频率(21例[27%])显著高于双重PCR方案呈阳性的频率(6例[8%])(P=0.002)。与单独检测相比,双重PCR方案的开发提高了敏感性,但仍显著低于Binax NOW尿抗原检测,且更耗时、成本更高。尿抗原检测是疑似重症肺炎球菌感染患者的首选非培养诊断方法。